Lee, Mary R.
Rohn, Matthew C. H.
Tanda, Gianluigi
Leggio, Lorenzo
Funding for this research was provided by:
NIH Clinical Center (Bench to Bedside Grant)
National Institute on Alcohol Abuse and Alcoholism (ZIA-AA000218)
National Institute on Drug Abuse (MDP)
Article History
First Online: 1 March 2016
Compliance with Ethical Standards
:
: The work was supported by (1) a Bench-to-Bedside (B2B) Grant [primary investigator [PI]: Lee) funded by the National Institutes of Health (NIH) Office of Behavioral and Social Sciences Research (OBSSR); (2) NIH intramural funding ZIA-AA000218 (Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology; PI: Leggio), jointly supported by the Division of Intramural Clinical and Biological Research of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the Intramural Research Program (IRP) of the National Institute on Drug Abuse (NIDA); and (3) the Medication Development Program of the NIDA IRP. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
: The authors, Mary R. Lee, Matthew C.H. Rohn, Gianluigi Tanda, and Lorenzo Leggio, declare that they have no conflicts of interest.